Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some core label-supported claims are accurate (indication, dosing/titration principles, and general interaction/exposure concept), but multiple claims are either unsupported or only partially supported by the provided label excerpts (notably brand-name equivalence, tardive dyskinesia etiology description, “capsule by mouth” specificity, fatigue, and counseling wording).
Category Scores
Accurate Statements
Valbenazine is used to treat tardive dyskinesia in adults.
Supported by label Indications and Usage.
Dosing for Ingrezza depends on the prescribed regimen and how the patient tolerates the medicine.
Supported by Recommended Dosage language about response and tolerability considerations.
Some drug interactions can change valbenazine exposure or increase side-effect risk.
Supported by Drug Interactions (clinically significant interactions affecting exposure and risk of exposure-related adverse reactions).
Unsupported Statements
Ingrezza 40 mg capsules are the branded form of valbenazine.
Not supported by the provided label excerpts (brand-name equivalence statement not present).
Tardive dyskinesia is a movement disorder that can result from long-term use of dopamine receptor-blocking agents.
Disease etiology/definition not provided in the provided label excerpts.
The medications mentioned include certain antidepressants, antifungals, antibiotics, or other neurologic drugs.
No such medication classes or examples are supported by the provided label excerpts (interaction table entries not listed in the claim).
Contradictions
Important Omissions
Boxed warning status and any boxed-warning-related counseling/requirements (if any) were not evaluated against the label because boxed warning content was not provided in the available excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are either unsupported or only partially supported, which could affect correct labeling interpretation (e.g., brand-equivalence, counseling wording, and unspecified interaction medication classes). Core interaction-exposure and somnolence/administration principles are partially supported, limiting risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts (brand-equivalence, tardive dyskinesia etiology/definition, and interaction medication examples), and some statements are only partially supported (capsule-by-mouth wording specificity; 'fatigue'; and counseling phrasing).
Suggested Improvement
Restrict claims to wording and concepts explicitly present in the provided label sections: (1) cite indication directly; (2) describe dosing as initial/titration and response/tolerability as stated; (3) describe administration as oral with or without food (and avoid unverified '40 mg capsules' phrasing); (4) use somnolence/sedation rather than 'fatigue' unless supported; (5) for interactions, reference exposure/risk for listed interaction categories rather than naming broad drug-class examples not present in the excerpt.